High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.

[1]  X. Wan,et al.  Elevated STMN1 promotes tumor growth and invasion in endometrial carcinoma , 2016, Tumor Biology.

[2]  Jia Liu,et al.  Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer , 2015, Tumor Biology.

[3]  G. Mills,et al.  Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients , 2014, OncoTarget.

[4]  H. Kuwano,et al.  Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma , 2014, Cancer science.

[5]  FIGO staging for carcinoma of the vulva, cervix, and corpus uteri , 2014, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[6]  K. Leslie,et al.  Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. , 2014, Gynecologic oncology.

[7]  C. Liu,et al.  Stathmin, interacting with Nf-κB, promotes tumor growth and predicts poor prognosis of pancreatic cancer. , 2014, Current molecular medicine.

[8]  L. Akslen,et al.  Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer , 2014, PloS one.

[9]  Zhou Wang,et al.  Retraction Note: STMN-1 is a potential marker of lymph node metastasis in distal esophageal adenocarcinomas and silencing its expression can reverse malignant phenotype of tumor cells , 2014, BMC Cancer.

[10]  Zhou Wang,et al.  STMN-1 is a potential marker of lymph node metastasis in distal esophageal adenocarcinomas and silencing its expression can reverse malignant phenotype of tumor cells , 2014, BMC Cancer.

[11]  O. Kim,et al.  Mechanism for the catastrophe-promoting activity of the microtubule destabilizer Op18/stathmin , 2013, Proceedings of the National Academy of Sciences.

[12]  K. Atkins,et al.  Women 50 Years Or Younger With Endometrial Cancer: The Argument for Universal Mismatch Repair Screening and Potential for Targeted Therapeutics , 2013, International Journal of Gynecologic Cancer.

[13]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[14]  K. Kalland,et al.  High Phospho-Stathmin(Serine38) Expression Identifies Aggressive Endometrial Cancer and Suggests an Association with PI3K Inhibition , 2013, Clinical Cancer Research.

[15]  Yanchao Hu,et al.  Low expression of stathmin in tumor predicts high response to neoadjuvant chemotherapy with docetaxel-containing regimens in locally advanced breast cancer. , 2012, Genetic testing and molecular biomarkers.

[16]  D. Miller,et al.  Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study , 2012 .

[17]  Hwee Tong Tan,et al.  Proteomic analysis of colorectal cancer metastasis: stathmin-1 revealed as a player in cancer cell migration and prognostic marker. , 2012, Journal of proteome research.

[18]  C. Cordon-Cardo,et al.  Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy. , 2011, The Journal of urology.

[19]  R. Drapkin,et al.  Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. , 2011, Gynecologic oncology.

[20]  J. Marcickiewicz,et al.  Stathmin Overexpression Identifies High-Risk Patients and Lymph Node Metastasis in Endometrial Cancer , 2011, Clinical Cancer Research.

[21]  L. Akslen,et al.  Evolution in Endometrial Cancer: Evidence From an Immunohistochemical Study , 2011, International Journal of Gynecologic Cancer.

[22]  S. Hsieh,et al.  Stathmin1 overexpression associated with polyploidy, tumor‐cell invasion, early recurrence, and poor prognosis in human hepatoma , 2010, Molecular carcinogenesis.

[23]  Jae Bong Kim,et al.  Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells , 2010, British Journal of Cancer.

[24]  D. Katsaros,et al.  Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel , 2009, Cancer.

[25]  I. Jonassen,et al.  Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation , 2009, Proceedings of the National Academy of Sciences.

[26]  Y. Oda,et al.  Overexpression of Class III β-Tubulin Predicts Good Response to Taxane-Based Chemotherapy in Ovarian Clear Cell Adenocarcinoma , 2009, Clinical Cancer Research.

[27]  F. Lovat,et al.  Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. , 2008, Molecular biology of the cell.

[28]  Zhuchu Chen,et al.  Identification of Novel Nasopharyngeal Carcinoma Biomarkers by Laser Capture Microdissection and Proteomic Analysis , 2008, Clinical Cancer Research.

[29]  M. Maiman,et al.  A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. , 2004, Gynecologic oncology.

[30]  R. Burger,et al.  Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[32]  G. Bepler,et al.  Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer , 2003, Oncogene.

[33]  David E. Misek,et al.  Overexpression of Oncoprotein 18 Correlates with Poor Differentiation in Lung Adenocarcinomas* , 2003, Molecular & Cellular Proteomics.

[34]  W. Hait,et al.  Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. , 2002, Cancer research.

[35]  Ximing J. Yang,et al.  Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features. , 2002, Cancer research.

[36]  G. Brattsand.  Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors , 2000, British Journal of Cancer.

[37]  O. Valenta.  [GYNECOLOGIC ONCOLOGY]. , 1963, Ceskoslovenska gynekologie.